News | March 02, 2021
DSM secures victory in patent infringement litigation against Anhui Tiger
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
This marks the second indication for which gumokimab has gained NDA review acceptance
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Subscribe To Our Newsletter & Stay Updated
